Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Illumina said on Tuesday that it has invested an undisclosed amount in Time Boost Capital, a genomics venture fund that plans to match funding raised by startups participating in the UK-based version of Illumina's accelerator program.

Population genomics and viral surveillance company Helix said Tuesday that it has begun a new partnership with Texas' Memorial Hermann Health System to launch a new population health program targeting 100,000 individuals.

Since Beckman Coulter began to develop in China more than 40 years ago, it has continued to increase local investment, firmly helped China's laboratory medicine, realized the localization of a number of products, and is committed to promoting leading science and technology to more people.

Cepheid and BioGX announced on Monday a collaboration to develop a monkeypox assay on the GeneXpert system. Financial and other terms of the deal were not disclosed.

In the past two years, due to the strong cash flow driven by COVID-19, the industrial parks of Chinese IVD enterprises have been ready to land.

Illumina has acquired IDbyDNA, a company developing metagenomic technology for infectious disease testing and pathogen surveillance, GenomeWeb has learned today.

An analysis of monkeypox virus (MPXV) genomes from the ongoing global outbreak has found that the samples cluster together, indicating a single origin for them.

Recently, Shenzhen Eurekabio Technology Co., Ltd. (hereinafter referred to as "Eurekabio") announced that it had completed the 100 million CNY of round B financing.

Israeli diagnostics firm Nucleix said on Wednesday that it has expanded the European Union label indication of its Bladder EpiCheck urothelial cancer test.

Fujirebio announced on Thursday that it is acquiring neurodegenerative disease diagnostic company ADx NeuroSciences for €40 million ($42.1 million).